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Abstract
Studies of mammalian prion diseases such as bovine spongiform encephalopathy have suggested
that different strains consist of prion proteins with different conformations. Two recent studies
of yeast prions have now formally demonstrated that multiple stable protein conformations are
the basis of strain variation. 
Published: 22 April 2004
Genome Biology 2004, 5:222
The electronic version of this article is the complete one and can be
found online at http://genomebiology.com/2004/5/5/222
© 2004 BioMed Central Ltd 
Transmissible spongiform encephalopathies (TSEs) are a
group of closely related neurodegenerative conditions of
animals and humans that includes sheep scrapie, chronic
wasting disease of deer and elk, bovine spongiform
encephalopathy (BSE) and human Creutzfeldt-Jakob disease
(CJD). TSEs attracted interest and considerable controversy
well before the epidemic of BSE and the subsequent appear-
ance of a new variant of human CJD, because of their extra-
ordinary features. It was once widely believed that TSEs
were caused by infectious agents containing a nucleic-acid
genome, but the prevailing view now attributes these dis-
eases to subcellular pathogens called ‘prions’, which are
defined as small proteinaceous infectious particles that lack
informational nucleic acid [1]. Although the precise molecu-
lar structure of the infectious agent has still not been defini-
tively identified, considerable evidence supports the
unorthodox hypothesis that prions are composed largely, if
not entirely, of a pathogenic conformation of the prion
protein (PrP), referred to as PrPSc, and that during the
disease process, PrPSc imposes its conformation on the
normal, host-encoded version of PrP (PrPC), resulting in the
exponential accumulation of PrPSc. 
One of the biggest challenges for this theory, called the prion
hypothesis, has been to explain the existence of multiple
strains of the infectious agent in the absence of informa-
tional nucleic acid; this characteristic convinced some inves-
tigators that the scrapie agent must be a virus [2-4].
Mammalian prion strains are classically defined in terms of
their differing incubation times and the different profiles of
pathological lesions that they produce in the central nervous
system of recipient animals. More recently, attempts have
been made to use biochemical and/or immunological prop-
erties of PrPSc as markers of prion strain differences [5,6].
Discussion of different strains in the context of the prion
hypothesis generally refers to the different conformational
states of mammalian or yeast prion proteins. Two recent
studies in yeast [7,8] confirm the predictions from earlier
studies of mammalian prions [9-14], which suggested that
strain specificity is linked to conformational differences
in PrPSc.
The discovery in the mid-1990s that certain phenotypic traits
in yeast were propagated by a mechanism similar to TSEs
[15,16] suggested that information transfer by such epigenetic
mechanisms was more widespread in nature than was once
appreciated, and the discovery did much to bolster the prion
hypothesis. Moreover, while progress on experimental verifi-
cation of the ‘protein-only’ prion hypothesis in the past 20
years has been considerable, the long experimental incuba-
tion times of TSEs and the difficulties associated with charac-
terization of PrPSc, including its extreme hydrophobicity and
tendency to aggregate, have provided formidable challenges
for studies of mammalian prion diseases. In contrast,
although the study of prion-like agents in yeast has not been
straightforward, yeast readily lends itself to genetic, cell bio-
logical and biochemical analysis, meaning that progress on
the study of yeast prions has been relatively rapid. The two most widely studied yeast prions are [URE3] [15],
the prion form of the protein Ure2p which is involved in the
regulation of nitrogen metabolism, and [PSI+] [16], which is
the prion isoform of the essential protein Sup35p, the yeast
counterpart of the animal translational termination factor
eRF3. As predicted for a prion-like mode of replication,
Sup35p is soluble inside [psi-] cells (and is thus equivalent to
PrPC) but forms insoluble fibrillar amyloid aggregates in
[PSI+] cells (equivalent to PrPSc). [PSI+] yeast cells are par-
tially defective in translation termination because accumula-
tion of self-replicating aggregates of Sup35p in [PSI+] cells
leads to depletion of the cellular pool of the termination
factor, resulting in an enhanced tendency of ribosomes to
read through nonsense mutations. The [PSI+] state is readily
assessed in a genetic background containing a nonsense
mutation in the ade1 gene. In the [psi-] state, yeast contain-
ing such a mutant allele do not grow on medium without
adenine and accumulate a red pigment on complete
medium, whereas the presence of the [PSI+] prion in
ade1 cells leads to read-through of UGA codons (nonsense
suppression), which partially restores growth on adenine-
deficient medium and results in white or pink colonies.
[PSI+] shows a range of phenotypic states - reminiscent of
mammalian prion strains - which differ from each other in
their levels of nonsense suppression, the involvement of
chaperone proteins, and in the solubility and activity of
Sup35p. Such [PSI+] variants can be identified on the basis
of the ade1 color phenotype. In previous studies, Weissman
and colleagues [17] impressively demonstrated induction of
the [PSI+] state by the introduction into [psi-] cells of a bac-
terially produced recombinant fragment of Sup35p, referred
to as Sup-NM, made up of residues 1-254. This fragment
consists of the amino-terminal glutamine- and asparagine-
rich region of Sup35p that is required for [PSI+] propaga-
tion, plus the highly charged middle region. In a study
recently published in Nature by the same group, Tanaka and
colleagues [7] used a new, highly efficient method for infect-
ing yeast with preformed Sup-NM amyloid fibers, combined
with genetic selection to identify the small numbers of yeast
cells converted to the [PSI+] state, to demonstrate that infec-
tion of yeast with different conformations of yeast prion pro-
teins results in the manifestation of different prion strains.
Previous studies [18] showed that overexpression of the
amino-terminal fragment Sup-NM leads to aggregation of
Sup35p and the appearance of a range of phenotypic [PSI+]
variants. Using a heterogenous preparation of Sup-NM
fibers preformed in vitro, Tanaka and coworkers [7] were
able to obtain a range of [PSI+] strains following introduc-
tion into [psi-] yeast. When extracts or partially purified
Sup35p proteins were prepared from the yeast cells contain-
ing the resulting [PSI+] strains and used to transform [psi-]
yeast, the different [PSI+] strains were faithfully propagated,
suggesting that the different strains of prion observed in
yeast transformed with pure protein arose from intrinsic
heterogeneity in the Sup-NM prions formed in vitro. In a
key experiment, Sup-NM amyloid fibers with different con-
formations were prepared in vitro at different temperatures,
allowing the investigators to directly test the role of protein
conformation in determining [PSI+] strain properties in vivo
(Figure 1). Tanaka and colleagues [7] found that the different
conformations of Sup-NM formed in vitro generated differ-
ent [PSI+] strains and, once formed, the conformation-
dependent strain characteristics were stably propagated in
successive generations of yeast cells. 
In a related paper appearing in the same issue of Nature,
Chih-Yen King and Ruben Diaz-Avalos [8] used a fusion
construct, referred to as Sup35(1-61)-GFP, consisting of the
green fluorescent protein (GFP) fused carboxy-terminally to
the first 61 amino-acid residues of Sup35p, to determine
whether diluted cell extracts prepared from yeast propagat-
ing various [PSI+] strains could be used to seed the assembly
of aggregates of recombinant Sup35(1-61)-GFP. When
exposed to recombinant Sup35(1-61)-GFP, the initial short
rod-shaped aggregates from the cell extracts elongated and
the fiber morphology of the original seeding strain was
maintained. Following incubation and sonication, the aggre-
gates were found to retain strain-specific infectivity upon
reintroduction into yeast. In an important final series of
experiments analogous to those described by Tanaka and
colleagues [7], King and Diaz-Avalos [8] demonstrated that
strain-specific [PSI+] infectivity could arise from self-assem-
bly of pure recombinant Sup35(1-61)-GFP prepared under
different buffering and temperature conditions in the
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Figure 1
A schematic representation of common aspects of the procedure that
Tanaka et al. [7] and King and Diaz-Avalos [8] used to generate multiple
[PSI+] strains by converting Sup35p protein to different aggregating
conformations in vitro. The [psi-] budding yeast cells (left) containing
normal Sup35p (circles) were made into spheroplasts (lacking some of the
cell wall; middle) into which preformed conformations of a recombinant
amino-terminal fragment of Sup35p (squares and triangles) were
introduced. This leads to a [PSI+] state (right), as assessed by plating on a
rich medium containing trace amounts of adenine; [PSI+] cells produce
white colonies on this medium whereas [psi-] cells produce red colonies
(not shown). Different conformations of Sup35p gave rise to
phenotypically distinct strains of [PSI+] cells. 
[psi−]
[PSI+]
[PSI+]
Conformation A
(temperature 1)
Conformation B
(temperature 2)
Strain A
Strain B
Spheroplastsabsence of yeast seeds. In agreement with the results of
Tanaka and colleagues [7], transformation of yeast cells with
these different amyloid preparations induced the formation
of distinct [PSI+] strains [8].
These two studies clearly demonstrate that Sup-NM or
Sup35(1-61)-GFP can be induced to adopt multiple, stable
conformations before entry into the cell and that these con-
formational differences are the basis of [PSI+] strain varia-
tion. This demonstration satisfies a core prediction of the
prion hypothesis and validates earlier studies of mammalian
prion diseases. Seminal studies linking the conformation of
PrPSc with prion strain arose from investigations of mink
prions that, upon transmission, produced different clinical
symptoms and produced PrPSc with different resistances to
proteinase-K digestion and altered amino-terminal pro-
teinase-K cleavage sites [9]. Such strain-specific conforma-
tional differences were also reproduced in cell-free
conversion systems [10,11]. Evidence supporting the hypoth-
esis that strain diversity is encoded in the tertiary structure
of PrPSc emerged from studies of the transmission of inher-
ited and sporadic human prion diseases in transgenic mice
[12-14]. Banding patterns of PrPSc forms with different gly-
cosylation patterns and sizes of PrPSc fragments following
proteinase-K treatment have also been used to determine
the strain of CJD cases [19,20]. In particular, a characteristic
type of glycosylated PrPSc observed in patients with variant
CJD and BSE-infected animals appears to distinguish vCJD
PrPSc from the patterns observed in classical CJD [21]. 
Notwithstanding criticisms that studies of phenotypic states in
yeast do not accurately reflect TSE infection [4], yeast prions
provide a powerful model for understanding the general prin-
ciples of protein-based inheritance with relevance to the mole-
cular mechanisms of mammalian amyloid diseases. The
challenge for investigators studying mammalian prions will be
to corroborate these studies in yeast by creating new infectious
material from pure recombinant PrP or from material synthe-
sized in vitro. Disappointingly, attempts to generate infectivity
from such approaches, let alone different prion strains, have
so far had uniformly negative results.
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